Drugs / MK-1248
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02553499 | Nov 2015 → Oct 2018 | — | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02553499 ↗ |
| Action | Activate | “MK-1248 is a humanized immunoglobulin G4 anti-GITR monoclonal antibody agonist.” PMID 32809217 ↗ Aug 2020 |
| Modality | Monoclonal antibody | “MK-1248 is a humanized immunoglobulin G4 anti-GITR monoclonal antibody agonist.” PMID 32809217 ↗ Aug 2020 |